During the recent session, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s traded shares were 81.64 million, with the beta value of the company hitting 0.35. At the last check today, the stock’s price was $0.59, reflecting an intraday gain of 58.67% or $0.22. The 52-week high for the CYCC share is $4.00, that puts it down -577.97 from that peak though still a striking 47.46% gain since the share price plummeted to a 52-week low of $0.31. The company’s market capitalization is $3.70M, and the average intraday trading volume over the past 10 days was 0.44 million shares, and the average trade volume was 1.64 million shares over the past three months.
Cyclacel Pharmaceuticals Inc (CYCC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. CYCC has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Cyclacel Pharmaceuticals Inc (CYCC) registered a 58.67% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 58.67% in intraday trading to $0.59, hitting a weekly high. The stock’s 5-day price performance is 81.47%, and it has moved by 31.36% in 30 days. Based on these gigs, the overall price performance for the year is -75.38%. The short interest in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is 66765.0 shares and it means that shorts have 0.03 day(s) to cover.
The consensus price target of analysts on Wall Street is $1, which implies an increase of 41.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1 and $1 respectively. As a result, CYCC is trading at a discount of -69.49% off the target high and -69.49% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 32.13%.
CYCC Dividends
Cyclacel Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
Cyclacel Pharmaceuticals Inc insiders own 4.82% of total outstanding shares while institutional holders control 18.03%, with the float percentage being 18.94%.
